champva glp 1 coverage Who Gets the Shot? GLP-1 Access by State MCT2D | 2023 Updates to

CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early Versus Late Alzheimers Disease

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

The Bottom Line GLP-1 medications remain valuable tools for appetite control and metabolic health, but many users encounter side effects that impact daily comfort especially dry mouth, altered taste, and unpredictable cravings

Tirzepatide was non-inferior to dulaglutide in reducing CV events, supporting a CV benefit in people with type 2 diabetes (Nicholls et al, 2025)

Missing a dose can affect appetite control and slow progress depending on timing and frequency

Mol Metab 55:101407